giovedì, 26 novembre 2020
Medinews
14 Settembre 2018

FDA Updates Venetoclax CLL Label With MRD Data

September 11, 2018 – The FDA has added minimal residual disease (MRD) data from the phase III MURANO trial to the label for venetoclax for its approved use in combination with rituximab for previously-treated patients with chronic lymphocytic leukemia (CLL). AbbVie, which is co-developing venetoclax with Roche, noted in a press release that, “MRD-negativity occurs when less than 1 CLL cell per 10,000 lymphocytes can be detected in the blood or … (leggi tutto)

TORNA INDIETRO